Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia)
Devi Andiani Putri
Department of Social and Administrative Pharmacy, Faculty of Pharmacy, Universitas Muhammadiyah Purwokerto, Banyumas, Central Java
Materials Science & Nanotechnology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Cost-Utility Analysis Addition of Bevacizumab to Standard Chemotherapy in KRAS-mutation Colorectal Cancer Devi Andiani Putri; Didik Setiawan; Muhammad Yamsun
PHARMACY: Jurnal Farmasi Indonesia (Pharmaceutical Journal of Indonesia) Jurnal Pharmacy, Vol. 22 No. 01 Juli 2025
Publisher : Pharmacy Faculty, Universitas Muhammadiyah Purwokerto

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

There is a high incidence of colorectal cancer in Indonesia. Colorectal cancer was ranked fourth with an incidence of 8.6% and a colon cancer mortality rate of 4% while rectal cancer was 3.6% in Indonesia. The addition of Bevacizumab to Standard chemotherapy (FOLFOX/FOLFIRI/XELOX) in KRAS-mutation colorectal cancer patients has better clinical outcomes; however, it has a very high cost in terms of colorectal cancer treatment. The objective of this study was to determine the utility and economic impact of adding Bevacizumab as an adjunct therapy for KRAS-mutation colorectal cancer patients. A Markov model was developed to estimate the Cost-utility analysis (CUA) using a societal perspective. Humanistic outcomes are expressed in the form of QALY (Quality-adjusted life years) using an EQ-5D-5L instrument with an Indonesian value set. Medical expenses data were collected from both RSUP Dr. Sardjito and patients. Utility data were obtained from interviews with 30 patients undergoing chemotherapy at the hospital. This study compared the cost and utility of patients receiving Bevacizumab supplementation or patients receiving standard chemotherapy alone. The societal perspective resulted in a cost-effectiveness ratio (ICER) of US$3.098 per QALY. The addition of Bevacizumab to standard chemotherapy in KRAS-mutation colorectal cancer patients is considerably cost-effective from a societal perspective.
Co-Authors Didik Setiawan Muhammad Yamsun